By Greg Hazley
Abernathy MacGregor Group is PR adviser to Sanofi-Aventis SA as the French drug company locks up a $20.1B deal to acquire Genzyme Corp.
Genzyme, which focuses on treating rare diseases, works with Publicis’ Kekst and Company.
The $74/share deal was announced by both companies on Feb. 16 following a nine-month pursuit by Sonofi, which made a $17.6B offer last July. The acquisition, which has cleared anti-trust approval in the U.S. and Europe, is expected to close in the second quarter.
Abernathy MacGregor’s New York office is supporting corporate communications for Paris-based Sanofi. Genzyme is based in Cambridge, Mass.
|